DDX39B: A Promising Drug Target for Cell Signaling Pathways (G7919)

Target Name: DDX39B

NCBI ID: G7919

DDX39B

DDX39B: A Promising Drug Target for Cell Signaling Pathways

The development of new pharmaceuticals is a critical process that involves the identification and characterization of potential drug targets. One of the most promising approaches in drug discovery is the use of gene expression arrays, which can identify potential biomarkers or drug targets in the human body. One of the most promising gene expression arrays is the Direct Repression Assay (DRA), also known as DDX39B (DX39B_HUMAN).

DDX39B is a gene that has been identified as a potential drug target in the human body. It is a non-coding RNA molecule that is located on chromosome 6p21.2. According to research, DDX39B is involved in cell signaling pathways, specifically in the regulation of cell adhesion and migration.

Expression of DDX39B

DDX39B is a gene that is expressed in almost all human tissues. It is expressed in the brain, heart, liver, and pancreas, among other organs. According to research, DDX39B is expressed at different levels in different tissues, with the highest levels of expression found in the brain.

Function of DDX39B

DDX39B is involved in several cell signaling pathways, including the regulation of cell adhesion and migration. It is a key regulator of theNotch signaling pathway, which is involved in the regulation of cell adhesion and survival.

Research has shown that DDX39B plays a critical role in the regulation of cell adhesion and migration. It is involved in the formation of tight junctions, which are specialized structures that mediate cell-cell communication. It is also involved in the regulation of cell migration, which is critical for the development and maintenance of tissues and organs.

Drug Target Potential

DDX39B is a promising drug target because of its involvement in several key cell signaling pathways. Its involvement in cell adhesion and migration makes it a potential target for drugs that are designed to modulate these processes.

One of the most promising approaches for targeting DDX39B is the use of small molecules. Research has shown that a number of small molecules have been shown to interact with DDX39B and to modulate its function. These small molecules include inhibitors of theNotch signaling pathway, which are known to inhibit the activity of DDX39B.

Another approach for targeting DDX39B is the use of antibodies. Research has shown that antibodies can be used to specifically target DDX39B and to modulate its function. These antibodies include monoclonal antibodies, which are laboratory-produced antibodies that are specific for a single target.

Conclusion

In conclusion, DDX39B is a gene that has been identified as a potential drug target in the human body. Its involvement in cell signaling pathways, including the regulation of cell adhesion and migration, makes it a promising target for small molecules and antibodies. Further research is needed to fully understand the potential of DDX39B as a drug target.

Protein Name: DExD-box Helicase 39B

Functions: Involved in nuclear export of spliced and unspliced mRNA. Assembling component of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and specifically associates with spliced mRNA and not with unspliced pre-mRNA. TREX is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NFX1 pathway. May undergo several rounds of ATP hydrolysis during assembly of TREX to drive subsequent loading of components such as ALYREF/THOC and CHTOP onto mRNA. Also associates with pre-mRNA independent of ALYREF/THOC4 and the THO complex. Involved in the nuclear export of intronless mRNA; the ATP-bound form is proposed to recruit export adapter ALYREF/THOC4 to intronless mRNA; its ATPase activity is cooperatively stimulated by RNA and ALYREF/THOC4 and ATP hydrolysis is thought to trigger the dissociation from RNA to allow the association of ALYREF/THOC4 and the NXF1-NXT1 heterodimer. Involved in transcription elongation and genome stability

The "DDX39B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX39B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets